Platelet to white blood cell ratio and prognosis in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether the ratio of platelets to white blood cells in your blood can help predict how the disease will progress. It's a simple blood test that might give doctors more information about your AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of acute myeloid leukemia (AML).
- You cannot have any other blood-related diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study tests a new lab method to screen for acute myeloid leukemia (AML), including a rare subtype called acute promyelocytic leukemia. It may help doctors diagnose and classify AML more quickly and accurately.
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This study looks at how blood and clotting are affected in people newly diagnosed with acute myeloid leukemia (AML) who receive a common intensive chemotherapy combination (idarubicin and cytarabine). The goal is to better understand blood-related side effects and improve care.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.